琥珀酸索利那新片治疗女性单纯性下尿路感染继发膀胱过度活动症状的临床疗效观察及护理  

Solifenacin Succinate Tablets and Nursing Interventions in Lower Urinary Tract Infection Women With Overactive Bladder Symptom

作　　者：刘军霞 卢建路[2] LIU Jun-xia;LU Jian-lu(Urology Surgery Department,the First Affiliated Hospital of Henan Polytechnic University,Jiaozuo 454000,China;Urology Surgery Department,the Second People s Hospital of Jiaozuo,Jiaozuo 454000,China)

机构地区：[1]河南理工大学第一附属医院泌尿外科,焦作454000 [2]焦作市第二人民医院泌尿外科,焦作454000

出　　处：《中国合理用药探索》2020年第6期70-74,共5页Chinese Journal of Rational Drug Use

摘　　要：目的:探究琥珀酸索利那新片在治疗女性单纯性下尿路感染继发膀胱过度活动症状(overactive bladder,OAB)中的价值及护理对策。方法:选择我院2017年5月~2019年5月纳入的114例女性单纯性下尿路感染继发OAB患者作为研究对象,遵照随机双盲法分成两组(n=57),研究组给予琥珀酸索利那新片+酒石酸托特罗定片,对照组给予酒石酸托特罗定片。治疗前后,测定所有研究对象的首次膀胱排尿感、膀胱顺应性、最大膀胱容量、逼尿无抑制收缩次数、最大尿流率,同时调查临床症状积分,分别记录治疗前、治疗后1周、2周及1个月的膀胱过度活动症评分(OABSS),观察两组不良反应的发生率,比较两组的临床疗效和安全性。结果:治疗前,两组的各项指标相比无统计学差异(P>0.05);治疗后,研究组的首次膀胱排尿感、膀胱顺应性、最大膀胱容量、逼尿无抑制收缩次数、最大尿流率优于对照组(P<0.05)。治疗前,两组的各项积分相比无统计学差异(P>0.05);治疗后研究组的尿急、日间尿频、夜尿、急迫性尿失禁评分均低于对照组(P<0.05)。治疗前,两组的OABSS评分无统计学差异(P>0.05);治疗后,研究组1周、2周及1个月的OABSS评分均低于对照组(P<0.05)。研究组不良反应发生率(5.26%)与对照组(10.53%)无统计学差异(P>0.05),但研究组满意度(94.74%)优于对照组(80.70%,P<0.05)。结论:琥珀酸索利那新片治疗女性单纯性下尿路感染继发OAB效果显著,可有效改善尿动力学参数,有助于改善相关症状,降低病情严重程度,减少不良反应产生,安全性较高,患者对治疗效果的满意度较高。Objective:To study the effect and value of Solifenacin Succinate Tablets and nursing interventions in lower urinary tract infection women with overactive bladder(OAB)symptom.Methods:From May 2017 to May 2019,114 women diagnosed with lower urinary tract infection with OAB in our hospital were included in the study and equally divided into two groups(n=74)according to double-blind method.Control group was treated with Tolterodine Tartrate tablets,and research group with additional Solifenacin Succinate Tablets on that bases.Initial sensation of urination,bladder compliance,maximum cystometric capacity,non-inhibited contraction frequency,maximum flow rate and symptom scores were measured.Overactive bladder symptom score(OABSS)were recorded before medication,after 1w,2w and 1m of medication.Adverse event,efficacy and safety were probed.Results:Before treatment,clinical indicators between groups showed no significant difference(P>0.05).After treatment,initial sensation of urination,bladder compliance,maximum cystometric capacity,non-inhibited contraction frequency and maximum flow rate in the research group were better than those of control group(P<0.05).Before treatment,symptom scores between groups showed no statistically significant difference(P>0.05).After treatment,urgent urination,daily frequent urination,nocturnal enuresis and urge urinary incontinence scores in the research group were lower than those of control group(P<0.05).OABSS was not different between groups before treatment(P>0.05 OABSS in the research group were lower than those of control group when detected 1w,2w and 1m after treatment(P<0.05).Adverse event rate between research group(5.26%)and control group(10.53%)showed no significant difference(P>0.05).Treatment satisfaction in the research group(94.74%)was significantly higher than that of control group(80.70%,P<0.05).Conclusion:Solifenacin Succinate Tablets are clinically proven to be effective in the treatment of lower urinary tract infection with OAB,which can improve the urine dynamic paramet

关 键 词：疗效观察 索利那新 膀胱过度活动症 下尿路感染 

分 类 号：R975[医药卫生—药品]